Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 50,000 shares at $185.00 ($9.3M) on 2015-03-18, disclosed to the SEC on 2015-03-20.
Scheduled sale ($9.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |